These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 29445162)

  • 41. A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma.
    Cheung BB; Kleynhans A; Mittra R; Kim PY; Holien JK; Nagy Z; Ciampa OC; Seneviratne JA; Mayoh C; Raipuria M; Gadde S; Massudi H; Wong IPL; Tan O; Gong A; Suryano A; Diakiw SM; Liu B; Arndt GM; Liu T; Kumar N; Sangfelt O; Zhu S; Norris MD; Haber M; Carter DR; Parker MW; Marshall GM
    Oncogene; 2021 Apr; 40(13):2367-2381. PubMed ID: 33658627
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens.
    Rodríguez-Hernández CJ; Mateo-Lozano S; García M; Casalà C; Briansó F; Castrejón N; Rodríguez E; Suñol M; Carcaboso AM; Lavarino C; Mora J; de Torres C
    Oncotarget; 2016 Mar; 7(13):16112-29. PubMed ID: 26893368
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2.
    Ding Y; Yang J; Ma Y; Yao T; Chen X; Ge S; Wang L; Fan X
    J Exp Clin Cancer Res; 2019 Dec; 38(1):498. PubMed ID: 31856871
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.
    Kang JH; Rychahou PG; Ishola TA; Qiao J; Evers BM; Chung DH
    Biochem Biophys Res Commun; 2006 Dec; 351(1):192-7. PubMed ID: 17055458
    [TBL] [Abstract][Full Text] [Related]  

  • 45.
    De Rosa P; Severi F; Zadran SK; Russo M; Aloisi S; Rigamonti A; Capranico G; Milazzo G; Perini G
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982482
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of an osteosarcoma model with MYCN amplification and TP53 mutation in hiPS cell-derived neural crest cells.
    Mukae K; Takenobu H; Endo Y; Haruta M; Shi T; Satoh S; Ohira M; Funato M; Toguchida J; Osafune K; Nakahata T; Kanda H; Kamijo T
    Cancer Sci; 2023 May; 114(5):1898-1911. PubMed ID: 36661413
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.
    Kroesen M; Nierkens S; Ansems M; Wassink M; Orentas RJ; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ
    Int J Cancer; 2014 Mar; 134(6):1335-45. PubMed ID: 24038106
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma.
    Zhong ZY; Shi BJ; Zhou H; Wang WB
    J Int Med Res; 2018 Mar; 46(3):1209-1220. PubMed ID: 29322842
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.
    Tateishi K; Iafrate AJ; Ho Q; Curry WT; Batchelor TT; Flaherty KT; Onozato ML; Lelic N; Sundaram S; Cahill DP; Chi AS; Wakimoto H
    Clin Cancer Res; 2016 Sep; 22(17):4452-65. PubMed ID: 27076630
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.
    Petroni M; Sardina F; Infante P; Bartolazzi A; Locatelli E; Fabretti F; Di Giulio S; Capalbo C; Cardinali B; Coppa A; Tessitore A; Colicchia V; Sahùn Roncero M; Belardinilli F; Di Marcotullio L; Soddu S; Comes Franchini M; Petricci E; Gulino A; Giannini G
    Cell Death Dis; 2018 Aug; 9(9):895. PubMed ID: 30166519
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression.
    Hagemann S; Misiak D; Bell JL; Fuchs T; Lederer MI; Bley N; Hämmerle M; Ghazy E; Sippl W; Schulte JH; Hüttelmaier S
    Mol Cancer; 2023 May; 22(1):88. PubMed ID: 37246217
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potential anti-neuroblastoma agents from Juniperus oblonga.
    Qiao Y; Sunada NK; Hatada AE; Lange I; Khutsishvili M; Alizade V; Atha D; Ko'omoa-Lange DL; Borris RP
    Biochem Biophys Res Commun; 2019 Aug; 516(3):733-738. PubMed ID: 31255282
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
    Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
    Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC-Driven Cancer Progression.
    Gao J; Jung M; Mayoh C; Venkat P; Hannan KM; Fletcher JI; Kamili A; Gifford AJ; Kusnadi EP; Pearson RB; Hannan RD; Haber M; Norris MD; Somers K; Henderson MJ
    Cancer Res; 2020 Sep; 80(17):3706-3718. PubMed ID: 32651259
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Downregulation of BORIS/CTCFL leads to ROS-dependent cellular senescence and drug sensitivity in MYCN-amplified neuroblastoma.
    Rao GK; Makani VKK; Mendonza JJ; Edathara PM; Patel N; Ramakrishna M; Cilamkoti P; Chiring Phukon J; Jose J; Bhadra U; Bhadra MP
    FEBS J; 2022 May; 289(10):2915-2934. PubMed ID: 34854238
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma.
    Ferrucci F; Ciaccio R; Monticelli S; Pigini P; di Giacomo S; Purgato S; Erriquez D; Bernardoni R; Norris M; Haber M; Milazzo G; Perini G
    Biochim Biophys Acta Gene Regul Mech; 2018 Mar; 1861(3):235-245. PubMed ID: 29408445
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MTHFD1 regulates the NADPH redox homeostasis in MYCN-amplified neuroblastoma.
    Guan J; Li M; Wang Y; Zhang Y; Que Y; Lu S; Wang J; Zhu J; Huang J; Zhen Z; Sun F; Song M; Zhang Y
    Cell Death Dis; 2024 Feb; 15(2):124. PubMed ID: 38336749
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MYCN amplification and ATRX mutations are incompatible in neuroblastoma.
    Zeineldin M; Federico S; Chen X; Fan Y; Xu B; Stewart E; Zhou X; Jeon J; Griffiths L; Nguyen R; Norrie J; Easton J; Mulder H; Yergeau D; Liu Y; Wu J; Van Ryn C; Naranjo A; Hogarty MD; Kamiński MM; Valentine M; Pruett-Miller SM; Pappo A; Zhang J; Clay MR; Bahrami A; Vogel P; Lee S; Shelat A; Sarthy JF; Meers MP; George RE; Mardis ER; Wilson RK; Henikoff S; Downing JR; Dyer MA
    Nat Commun; 2020 Feb; 11(1):913. PubMed ID: 32060267
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Downregulated NORAD in neuroblastoma promotes cell proliferation via chromosomal instability and predicts poor prognosis.
    Yu Y; Chen F; Jin Y; Yang Y; Wang S; Zhang J; Chen C; Zeng Q; Han W; Wang H; Guo Y; Ni X
    Acta Biochim Pol; 2020 Dec; 67(4):595-603. PubMed ID: 33326736
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Wnt signalling is a bi-directional vulnerability of cancer cells.
    Duffy DJ; Krstic A; Schwarzl T; Halasz M; Iljin K; Fey D; Haley B; Whilde J; Haapa-Paananen S; Fey V; Fischer M; Westermann F; Henrich KO; Bannert S; Higgins DG; Kolch W
    Oncotarget; 2016 Sep; 7(37):60310-60331. PubMed ID: 27531891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.